Presentation Summary : Allred Immunohistochemistry Score Proportion ... Odds Ratio for Treatment Failure According to Tumor HER2 Status in Patients Treated with Endocrine Agents ...
Source : http://www.projectsinknowledge.com/Activity/slides/1808.01.ppt
Presentation Summary : Historical overview of FDA regulation of digital pathology imaging applications: the safety and effectiveness issues Tremel A. Faison, MS, RAC, SCT(ASCP)
Source : http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/HematologyandPathologyDevicesPanel/UCM201450.ppt
Presentation Summary : Introduction. The 2007 guideline created a diagnostic algorithm for HER2 testing by acceptable testing methods of immunohistochemisty (IHC) and fluorescence in situ ...
Source : http://www.cap.org/apps/docs/committees/immunohistochemistry/her2_presentation.pptx
Presentation Summary : Treatment of HER2-Positive Gastroesophageal Carcinoma Manish A. Shah, MD Director, Gastrointestinal Oncology Weill Cornell Medical College NewYork-Presbyterian Hospital
Source : http://s3.amazonaws.com/GECarcinoma/CCO_GE_Carcinoma_Shah_Slides.ppt
Presentation Summary : ... (HER2+), and TN cancers. Data are means ± SEM from three cases per subtype relative to the background (tumor cells cross without the presence of macrophages).
Source : http://stke.sciencemag.org/highwire/powerpoint/6069804%3Fppt_destination%3Dcontent/7/353/ra112.full
Presentation Summary : biotherapy.vc.ons.org
Source : http://biotherapy.vc.ons.org/file_depot/0-10000000/0-10000/3359/folder/108851/what+new+in+her+2+posted.pptx
Presentation Summary : ESMO 2010 HER2-positive, locally advanced or metastatic BC; previously received trastuzumab-based therapy Lapatinib (1250 mg/day) (Days 1–21) + Capecitabine ...
Source : http://cdn2.imng.com/fileadmin/images/onc/slideshows/NovelHer-2_targeted_agents.2.25.11.ppt